Analysis of the prophylactic effect of nucleosides against reactivation of HBV in HBsAg-positive patients with non-hepatic tumors after chemotherapy

To investigate the efficacy of nucleosides as a prophylactic agent against reactivation of hepatitis B virus (HBV) in HBsAg-positive patients with non-hepatic tumors after chemotherapy. Fifty-eight patients with non-hepatic tumors were divided into prevention group and control group. The patients of...

Full description

Saved in:
Bibliographic Details
Published inZhōnghuá zhŏngliú zázhì Vol. 32; no. 6; p. 459
Main Authors Zhang, Hao-Ye, Liu, Zhen-Guo, Zhang, Zhen, Gong, Huan-Yu
Format Journal Article
LanguageChinese
Published China 01.06.2010
Subjects
Adult
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Antiviral Agents - therapeutic use
Breast Neoplasms - blood
Breast Neoplasms - drug therapy
Female
Follow-Up Studies
Guanine - analogs & derivatives
Guanine - therapeutic use
Hepatitis B - drug therapy
Hepatitis B - prevention & control
Hepatitis B Surface Antigens - blood
Hepatitis B virus - physiology
Humans
Lamivudine - therapeutic use
Lung Neoplasms - blood
Lung Neoplasms - drug therapy
Lymphoma - blood
Lymphoma - drug therapy
Male
Middle Aged
Nucleosides - therapeutic use
Pyrimidinones - therapeutic use
Retrospective Studies
Thymidine - analogs & derivatives
Virus Activation - drug effects
Online AccessGet more information

Cover

More Information
Summary:To investigate the efficacy of nucleosides as a prophylactic agent against reactivation of hepatitis B virus (HBV) in HBsAg-positive patients with non-hepatic tumors after chemotherapy. Fifty-eight patients with non-hepatic tumors were divided into prevention group and control group. The patients of prevention group received nucleosides as a prophylactic agent before chemotherapy and were compared with the control ones about the clinical manifestation of HBV reactivation. Then, the patients of the control group were divided into three groups according to antiviral drugs, use or not and time of the use. The patients having HBV reactivation but never received nucleosides were included in the group A, the patients receiving nucleosides after having HBV reactivation were divided into the group B, and the patients receiving nucleosides before HBV reactivation were divided into the group C. The progression, prognosis and curative effect among the three groups were compared. The rate of HBV reactivation, incidence o
ISSN:0253-3766